Isabel Garau

1.2k total citations
21 papers, 255 citations indexed

About

Isabel Garau is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Isabel Garau has authored 21 papers receiving a total of 255 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Isabel Garau's work include Cancer Treatment and Pharmacology (7 papers), Advanced Breast Cancer Therapies (6 papers) and HER2/EGFR in Cancer Research (5 papers). Isabel Garau is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Advanced Breast Cancer Therapies (6 papers) and HER2/EGFR in Cancer Research (5 papers). Isabel Garau collaborates with scholars based in Spain, France and Italy. Isabel Garau's co-authors include Jorge Sastre‐Serra, Jordi Oliver, Pilar Roca, Adamo Valle, Élisabeth Monnet, Jean Faivre, L. Raymond, Rafael Marcos‐Gragera, M‐D Chirlaque and María‐José Sánchez and has published in prestigious journals such as Cancer Research, Free Radical Biology and Medicine and British Journal of Cancer.

In The Last Decade

Isabel Garau

19 papers receiving 248 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Isabel Garau Spain 9 117 68 46 37 35 21 255
Kazimierz Drosik Poland 6 80 0.7× 65 1.0× 37 0.8× 49 1.3× 50 1.4× 13 210
Annika Lenz United States 5 118 1.0× 52 0.8× 54 1.2× 47 1.3× 38 1.1× 10 261
R. Nishimura Japan 11 85 0.7× 99 1.5× 36 0.8× 34 0.9× 60 1.7× 34 351
Audrey Jung Germany 13 167 1.4× 97 1.4× 59 1.3× 37 1.0× 48 1.4× 30 367
Bekir Öztürk Türkiye 12 122 1.0× 53 0.8× 24 0.5× 25 0.7× 66 1.9× 27 351
N.M. Forones Brazil 8 107 0.9× 61 0.9× 40 0.9× 33 0.9× 68 1.9× 18 278
P. Boffetta France 6 94 0.8× 85 1.3× 80 1.7× 42 1.1× 30 0.9× 6 319
M.–C. Boutron–Ruault France 7 118 1.0× 44 0.6× 70 1.5× 41 1.1× 24 0.7× 14 345
March E. Seabrook United States 9 75 0.6× 46 0.7× 100 2.2× 13 0.4× 21 0.6× 12 190
Ewa Jaworowska Poland 9 39 0.3× 85 1.3× 24 0.5× 21 0.6× 39 1.1× 30 255

Countries citing papers authored by Isabel Garau

Since Specialization
Citations

This map shows the geographic impact of Isabel Garau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabel Garau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabel Garau more than expected).

Fields of papers citing papers by Isabel Garau

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isabel Garau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabel Garau. The network helps show where Isabel Garau may publish in the future.

Co-authorship network of co-authors of Isabel Garau

This figure shows the co-authorship network connecting the top 25 collaborators of Isabel Garau. A scholar is included among the top collaborators of Isabel Garau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isabel Garau. Isabel Garau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Antón, Antonio, Isabel Garau, N. Afonso, et al.. (2018). Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study. Clinical Breast Cancer. 19(2). 105–112. 11 indexed citations
2.
3.
Nucíforo, Paolo, Aleix Prat, Antonio Llombart‐Cussac, et al.. (2017). Tumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial. Annals of Oncology. 28. v46–v46. 7 indexed citations
4.
Garcı́a, Jacinto, Sònia Servitja, Ana Santaballa, et al.. (2017). Abstract P6-09-33: CASCADE study: Rapid survival decline per treatment line in metastatic breast cancer. Cancer Research. 77(4_Supplement). P6–9.
5.
Lao, J., Isabel Garau, N. Afonso, et al.. (2016). MERIBEL study: Single-agent eribulin as first-line therapy for taxane-resistant HER2[-] metastatic breast cancer (MBC) patients (pts). Annals of Oncology. 27. vi73–vi73. 1 indexed citations
6.
Servitja, Sònia, Ana Santaballa, Jacinto Garcı́a, et al.. (2016). CASCADE study: pronounced decline in treatment efficacy through the metastatic life of breast cancer patients. Annals of Oncology. 27. vi76–vi76. 3 indexed citations
7.
Barni, Sandro, et al.. (2016). Burden of advanced breast cancer for patients and caregivers in Europe: comparison of two treatment forms of vinorelbine, oral and intravenous. Current Medical Research and Opinion. 32(11). 1807–1812. 9 indexed citations
8.
Zamora, Pilar, et al.. (2016). Abstract P3-07-39: CASCADE study: Treatment and clinical outcomes of metastatic breast cancer by tumor immunophenotypes. Cancer Research. 76(4_Supplement). P3–7. 1 indexed citations
9.
10.
11.
Sastre‐Serra, Jorge, Mercedes Nadal‐Serrano, Daniel Gabriel Pons, et al.. (2013). The oxidative stress in breast tumors of postmenopausal women is ERα/ERβ ratio dependent. Free Radical Biology and Medicine. 61. 11–17. 20 indexed citations
12.
Marcos‐Gragera, Rafael, Marina Pollán, M‐D Chirlaque, et al.. (2010). Attenuation of the epidemic increase in non-Hodgkin's lymphomas in Spain. Annals of Oncology. 21. iii90–iii96. 23 indexed citations
13.
Sastre‐Serra, Jorge, Adamo Valle, Isabel Garau, Jordi Oliver, & Pilar Roca. (2009). Estrogen down-regulates uncoupling proteins and increases oxidative stress in breast cancer. Free Radical Biology and Medicine. 48(4). 506–512. 85 indexed citations
14.
Reyes, José, et al.. (2007). Mejoría de la supervivencia de la poliposis adenomatosa familiar después del establecimiento de un registro. Medicina Clínica. 129(2). 51–52. 8 indexed citations
15.
Condé, P., et al.. (2006). Treatment of medical databases and their graphical representation on the Internet. Medical Informatics and the Internet in Medicine. 31(3). 195–204. 1 indexed citations
16.
17.
Partanen, Timo, Wolfgang Ahrens, María Sala, et al.. (2002). Assessment of Feasibility of Workplace Health Promotion. Preventive Medicine. 35(3). 232–240. 8 indexed citations
18.
Monnet, Élisabeth, Jean Faivre, L. Raymond, & Isabel Garau. (1999). Influence of stage at diagnosis on survival differences for rectal cancer in three European populations. British Journal of Cancer. 81(3). 463–468. 26 indexed citations
19.
Monnet, Élisabeth, Jean Faivre, L. Raymond, & Isabel Garau. (1998). Comparability of colorectal cancer survival data in three European population-based registries.. PubMed. 7(2). 127–34. 10 indexed citations
20.
Garau, Isabel, Enric Benito, F. Xavier Bosch, et al.. (1994). Blood transfusion has no effect on colorectal cancer survival. A population-based study. European Journal of Cancer. 30(6). 759–764. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kazimierz Drosik Breakdown of academic impact, for papers by Annika Lenz Breakdown of academic impact, for papers by R. Nishimura Breakdown of academic impact, for papers by Audrey Jung Breakdown of academic impact, for papers by Bekir Öztürk Breakdown of academic impact, for papers by N.M. Forones Breakdown of academic impact, for papers by P. Boffetta Breakdown of academic impact, for papers by M.–C. Boutron–Ruault Breakdown of academic impact, for papers by March E. Seabrook Breakdown of academic impact, for papers by Ewa Jaworowska
Rankless by CCL
2026